ENTITY
Hangzhou Tigermed Consulting (A)

Hangzhou Tigermed Consulting (A) (300347 CH)

142
Analysis
Health Care • China
Hangzhou Tigermed Consulting Company Limited provides professional clinical research services for domestic and foreign pharmaceutical and health-related research and development. The Company's main services include clinical trial technology services, data management, and statistical analysis.
more
bearish•WuXi AppTec
•28 Nov 2018 05:57

WuXi AppTech IPO Update: Figuring Out the Right AH Premium

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
931 Views
Share
bullish•WuXi AppTec
•21 Nov 2018 10:41

Wuxi Apptec 药明康德 IPO: Welcome to the A/H Universe

WuXi Apptec is set to be the newest A/H pair with its upcoming HK listing that is set to raise USD 1 billion. The A-share (603289 CH) recorded 15...

Share
bearish•WuXi AppTec
•20 Nov 2018 20:34

WuXi AppTech IPO Trading Update: What’s up with the Poor Cash Conversion?

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
1.1k Views
Share
bullish•WuXi AppTec
•20 Nov 2018 14:15

WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different

Following a fast track A-share listing in May, WuXi AppTec is planning to raise USD 1 bn via an A+H listing. Wuxi AppTec is part of the Wuxi...

Logo
1.7k Views
Share
bullish•WuXi AppTec
•19 Nov 2018 06:57

WuXi AppTech IPO Preview: Pharmed Out

WuXi AppTec Co Ltd (603259 CH) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
1.3k Views
Share
x